102 related articles for article (PubMed ID: 24665087)
1. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: where antibody imaging dares to tread.
Marquez BV; Zheleznyak A; Lapi SE
J Nucl Med; 2014 May; 55(5):708-9. PubMed ID: 24665087
[No Abstract] [Full Text] [Related]
2. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
[TBL] [Abstract][Full Text] [Related]
3. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
[TBL] [Abstract][Full Text] [Related]
4. Hepatocelluar carcinoma in an accessory lobe of the liver revealed by 11C-acetate PET with a negative finding on FDG imaging.
Huo L; Dang Y; Feng R; Zhuang H; Li F
Clin Nucl Med; 2012 Apr; 37(4):393-5. PubMed ID: 22391716
[No Abstract] [Full Text] [Related]
5. Imaging of somatostatin receptor subtype 2 in advanced hepatocellular carcinoma by 68Ga-DOTATOC PET.
Freesmeyer M; Schulz S; Knösel T; Settmacher U
Nuklearmedizin; 2009; 48(3):N17-8. PubMed ID: 19588574
[No Abstract] [Full Text] [Related]
6. Sarcomatoid hepatocellular carcinoma diagnosed by FDG PET/CT.
Mi B; Wan W; Yu C; You X; Xu Q
Clin Nucl Med; 2011 Oct; 36(10):925-7. PubMed ID: 21892049
[No Abstract] [Full Text] [Related]
7. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
8. Letter to the editor regarding "PET imaging of hepatocellular carcinoma by targeting tumor‑associated endothelium using [
Li Z
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):638. PubMed ID: 36251024
[No Abstract] [Full Text] [Related]
9. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
[TBL] [Abstract][Full Text] [Related]
10. Imaging of the hepatocellular carcinoma using dynamic positron emission tomography with nitrogen-13 ammonia.
Hayashi N; Tamaki N; Yonekura Y; Senda M; Saji H; Yamamoto K; Konishi J; Torizuka K
J Nucl Med; 1985 Mar; 26(3):254-7. PubMed ID: 2983053
[TBL] [Abstract][Full Text] [Related]
11. Important factors determining prognosis based on SUVmax in PET imaging.
Şahin E; Akcan AB
Turk J Gastroenterol; 2015 Sep; 26(5):442. PubMed ID: 26215070
[No Abstract] [Full Text] [Related]
12. PET scan with 11C-acetate for the imaging of liver masses: report of a false positive case.
Lhommel R; Annet L; Bol A; Gigot JF; Sempoux C; Mathieu I; Seret M; Lonneux M
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):629. PubMed ID: 15549295
[No Abstract] [Full Text] [Related]
13. Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma.
Kawamura E; Shiomi S; Kotani K; Kawabe J; Hagihara A; Fujii H; Uchida-Kobayashi S; Iwai S; Morikawa H; Enomoto M; Murakami Y; Tamori A; Kawada N
J Gastroenterol Hepatol; 2014 Sep; 29(9):1722-7. PubMed ID: 24730671
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma tumour thrombus in a re-canalised para-umbilical vein: detection by 18-fluoro-2-deoxyglucose positron emission tomography imaging.
Beadsmoore CJ; Cheow HK; Sala E; Lomas DJ; Gibbs P; Save V; Alison ME; Balan KK
Br J Radiol; 2005 Sep; 78(933):841-4. PubMed ID: 16110108
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET for hepatocellular carcinoma presenting with portal vein tumor thrombus.
Hanajiri K; Mitsui H; Maruyama T; Kondo Y; Shiina S; Omata M; Nakagawa K
J Gastroenterol; 2005 Oct; 40(10):1005-6. PubMed ID: 16261443
[No Abstract] [Full Text] [Related]
16. A hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma detected by F-18 FDG PET/CT imaging.
Pan JH; Dong MJ; Ouyang XB
Clin Nucl Med; 2011 Dec; 36(12):1137-9. PubMed ID: 22064094
[No Abstract] [Full Text] [Related]
17. Yttrium-90 time-of-flight PET/CT is superior to Bremsstrahlung SPECT/CT for postradioembolization imaging of microsphere biodistribution.
Kao YH; Tan EH; Ng CE; Goh SW
Clin Nucl Med; 2011 Dec; 36(12):e186-7. PubMed ID: 22064104
[No Abstract] [Full Text] [Related]
18. Fluoromethylcholine PET in recurrent multifocal hepatoma.
Lenzo NP; Anderson J; Campbell A; Morandeau L; De Grado TR
Australas Radiol; 2007 Dec; 51 Suppl():B299-302. PubMed ID: 17991090
[TBL] [Abstract][Full Text] [Related]
19. Early dynamic PET imaging shows hypervascularization as exact as contrast-enhanced MR.
Freesmeyer M; Lopatta E; Schierz JH; Steenbeck J; Opfermann T; Settmacher U
Nuklearmedizin; 2012; 51(1):N10-1. PubMed ID: 22336884
[No Abstract] [Full Text] [Related]
20. Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma.
Li S; Beheshti M; Peck-Radosavljevic M; Oezer S; Grumbeck E; Schmid M; Hamilton G; Kapiotis S; Dudczak R; Kletter K
Liver Int; 2006 Oct; 26(8):920-7. PubMed ID: 16953831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
